Compare SMX Security Matters plc (SMX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs Viatris Inc — how do they compare? SMX Security Matters plc trades at $3.8 (market cap $4.13M), while Viatris Inc trades at $17.53 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4849.9× SMX Security Matters plc's market cap, and Viatris Inc pays a 2.75% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 21 Days and Viatris Inc for 57 Days on average.
| SMX | VTRS | |
|---|---|---|
Market Cap | $4.13M | $20.03B |
Volume | 124,362 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $74.08K | $18.27 |
52-Week Low | $3.79 | $9.74 |
Typical Hold Time | 21 Days | 57 Days |
Enterprise Value | -$27.20M | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $4.21, up 7.95% today, but exhibits severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22% for 2025. The technical outlook is bearish based on moving averages, though oscillators like the RSI signal oversold conditions. Recent news highlights the company's focus on its Digital Material Passport platform for recycled plastics and material traceability, aiming to capitalize on circular economy trends.
The investment outlook is highly speculative. While the stock appears cheap on P/B (0.09) and EV/EBITDA (0.02) multiples, this reflects extreme financial losses and operational cash burn. Positive media coverage contrasts with the fundamental reality, creating significant risk. Upside depends entirely on the successful commercialization of its technology, which remains unproven given the current lack of revenue.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
